Lupus Research Alliance Grants Inaugural Awards to 11 Researchers Focused on Engineered Cell Therapies for Lupus
The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on...
Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus
Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus
New York, NY– June 27, 2019. The Lupus Research Alliance (LRA) and clinical research affiliate, Lupus Therapeutics, broadened a collaboration with Bristol-Myers Squibb (BMS) to study the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN) – kidney damage affecting about 50 percent of people with lupus. This expands the existing collaboration in systemic lupus erythematosus (SLE).
BMS-986165 selectively inhibits the action of tyrosine kinase 2 (TYK2), an enzyme involved in many autoimmune diseases, including lupus and lupus nephritis.
The full press release is available on the Lupus Therapeutics website.
